美国国立卫生研究院(NIH)执行会议摘要:制定医疗对策以挽救阿片类药物引起的呼吸抑制(跨机构科学会议)-2019 年 8 月 6/7 日。
National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)-August 6/7, 2019.
机构信息
National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), Bethesda, MD, USA.
National Institute of Drug Abuse/National Institutes of Health (NIDA/NIH), Bethesda, MD, USA.
出版信息
J Med Toxicol. 2020 Jan;16(1):87-105. doi: 10.1007/s13181-019-00750-x. Epub 2019 Dec 18.
On August 6th, 2019, a two-day trans-agency scientific meeting was convened by the United States (U.S.) National Institute of Allergy and Infectious Diseases (NIAID/NIH) on the research and development of medical countermeasures (MCMs) and treatment strategies to mitigate synthetic opioid-induced toxicities. This trans-agency meeting was an initiative of the Chemical Countermeasures Research Program (CCRP) and organized by the NIAID in collaboration with the National Institute of Drug Abuse (NIDA), the Biomedical Advanced Research and Development Authority (BARDA), the Food and Drug Administration (FDA), and the Defense Threat Reduction Agency (DTRA). The CCRP is part of the larger NIH biodefense research program coordinated by NIAID, which also includes MCM research and development programs against biological, radiological, and nuclear threats. Its overarching goal is to integrate cutting-edge research and technological advances in science and medicine to enhance the nation's medical response capabilities during and after a public health emergency involving the deliberate or accidental release of toxic chemicals. The potential of a mass casualty public health event involving synthetic opioids is a rapidly growing concern. As such, the overall goals of this trans-agency meeting are to better understand opioid-induced toxicities and advance the development of MCMs to mitigate and reverse opioid-induced respiratory depression (OIRD) to prevent consequential mortality. The primary objectives of the meeting were (1) highlight the latest research on mechanisms of OIRD and related toxicities, animal models, diagnostics, delivery technologies, and emerging new treatment options to prevent lethality; (2) identify current knowledge gaps to advance medical countermeasure development; (3) hear from the U.S. FDA on regulatory considerations to support new technology and treatment approaches; and (4) provide a forum for networking and collaborative partnerships. To accomplish this, a diverse group of almost 200 US domestic and international subject matter experts spanning fundamental and translational research from academia, industry, and government came together in-person to share their collective expertise and experience in this important field. This report briefly summarizes the information presented throughout the meeting, which was also webcast live in its entirety to registered remote attendees.
2019 年 8 月 6 日,美国(U.S.)国家过敏和传染病研究所(NIAID/NIH)召开了为期两天的跨机构科学会议,讨论医疗对策(MCMs)和治疗策略的研究与开发,以减轻合成阿片类药物引起的毒性。此次跨机构会议是化学对策研究计划(CCRP)的一项倡议,由 NIAID 与国家药物滥用研究所(NIDA)、生物医学高级研究与发展局(BARDA)、食品和药物管理局(FDA)以及国防威胁降低局(DTRA)合作组织。CCRP 是 NIAID 协调的更大 NIH 生物防御研究计划的一部分,该计划还包括针对生物、放射性和核威胁的 MCM 研究与开发计划。其总体目标是整合科学和医学领域的前沿研究和技术进步,以增强国家在涉及故意或意外释放有毒化学物质的公共卫生紧急情况下的医疗应对能力。涉及合成阿片类药物的大规模伤亡公共卫生事件的潜在风险是一个日益严重的问题。因此,此次跨机构会议的总体目标是更好地了解阿片类药物引起的毒性,并推进 MCM 的开发,以减轻和逆转阿片类药物引起的呼吸抑制(OIRD),以防止致命后果。会议的主要目标是:(1) 强调关于 OIRD 和相关毒性、动物模型、诊断、输送技术以及预防致死性的新兴新治疗选择的最新研究;(2) 确定推进医疗对策发展的当前知识空白;(3) 听取美国 FDA 关于支持新技术和治疗方法的监管考虑的意见;以及 (4) 提供一个网络和合作关系的论坛。为了实现这一目标,一个由近 200 名来自美国国内外的主题专家组成的多元化小组,涵盖了学术界、工业界和政府的基础研究和转化研究,齐聚一堂,分享他们在这一重要领域的集体专业知识和经验。本报告简要总结了会议期间介绍的信息,会议还进行了现场直播,向注册的远程参会者全程直播。
相似文献
Clin Pharmacol Ther. 2021-3
Toxicol Lett. 2020-9-8
Clin Pharmacol Ther. 2021-3
Radiat Res. 2022-4-1
Disaster Med Public Health Prep. 2024-2-22
Radiat Res. 2022-11-1
引用本文的文献
AAPS PharmSciTech. 2022-5-16
Clin Pharmacol Ther. 2021-3
本文引用的文献
Sens Actuators B Chem. 2019-10-1
Toxicol Lett. 2020-2-15
ACS Appl Bio Mater. 2019-8-19
NPJ Digit Med. 2019-6-19
J Pharmacol Exp Ther. 2019-4-2